|
|
Suppliers for
Raltegravir potassium salt
|
Properties | CAS |
871038-72-1 | Formula |
C20H20FKN6O5 |
|
|
15 Registered suppliers
Molecular Formula: C20H20FN6O5.K Molecular Weight: 482.511 HS Code: 2934990002
Molecular Formula: C20H20FN6O5.K Molecular Weight: 482.511 HS Code: 2934990002
Molecular Formula: C20H20FN6O5.K Molecular Weight: 482.511 HS Code: 2934990002
Molecular Formula: C20H20FN6O5.K Molecular Weight: 482.511 HS Code: 2934990002
Description : Raltegravir is a potent, selective, and orally bioavailable inhibitor of HIV integrase (IC50 = 15 nM). It is metabolized primarily by uridine diphosphate glucuronosyltransferase 1A. Raltegravir has long-term efficacy and safety in managing HIV-1 infection in adults, children, and adolescents. - Molecular Weight :482.514
- Melting Point :155-157˚C (dec.)
- Purity :98%
Molecular Formula : C20H20FKN6O5 Canonical SMILES : CC1=NN=C(O1)C(=O)NC(C)(C)C2=NC(=C(C(=O)N2C)[O-])C(=O)NCC3=CC=C(C=C3)F.[K+] InChI : InChI=1S/C20H21FN6O5.K/c1-10-25-26-17(32-10)16(30)24-20(2,3)19-23-13(14(28)18(31)27(19)4)15(29)22-9-11-5-7-12(21)8-6-11;/h5-8,28H,9H2,1-4H3,(H,22,29)(H,24,30);/q;+1/p-1 InChIKey : IFUKBHBISRAZTF-UHFFFAOYSA-M Solubility : In Vitro: H2O: 25 mg/mL (51.81 mM; Need ultrasonic) DMSO : 6 mg/mL (12.43 mM; Need ultrasonic) In Vivo: 1.Add each solvent one by one: 10% DMSO > > 90% corn oil Solubility: ≥ 0.6 mg/mL (1.24 mM); Clear solution 2.Add each solvent one by one: 10% DMSO > > 40% PEG300 > > 5% Tween-80 > > 45% saline Solubility: ≥ 0.6 mg/mL (1.24 mM); Clear solution 3.Add each solvent one by one: 10% DMSO > > 90% (20% SBE-β-CD in saline) Solubility: ≥ 0.6 mg/mL (1.24 mM); Clear solution Appearance : White crystalline powder Application : Anti-HIV Agents Storage : Powder: -20°C: 3 years 4°C: 2 years In solvent: -80°C: 6 months -20°C: 1 month Synonyms : MK-0518; MK 0518; MK0518; Raltegravir
More details are to be found here
Description : Raltegravir is a potent, selective, and orally bioavailable inhibitor of HIV integrase (IC50 = 15 nM). It is metabolized primarily by uridine diphosphate glucuronosyltransferase 1A. Raltegravir has long-term efficacy and safety in managing HIV-1 infection in adults, children, and adolescents. - Molecular Weight :482.514
- Melting Point :155-157˚C (dec.)
- Purity :98%
Molecular Formula : C20H20FKN6O5 Canonical SMILES : CC1=NN=C(O1)C(=O)NC(C)(C)C2=NC(=C(C(=O)N2C)[O-])C(=O)NCC3=CC=C(C=C3)F.[K+] InChI : InChI=1S/C20H21FN6O5.K/c1-10-25-26-17(32-10)16(30)24-20(2,3)19-23-13(14(28)18(31)27(19)4)15(29)22-9-11-5-7-12(21)8-6-11;/h5-8,28H,9H2,1-4H3,(H,22,29)(H,24,30);/q;+1/p-1 InChIKey : IFUKBHBISRAZTF-UHFFFAOYSA-M Solubility : In Vitro: H2O: 25 mg/mL (51.81 mM; Need ultrasonic) DMSO : 6 mg/mL (12.43 mM; Need ultrasonic) In Vivo: 1.Add each solvent one by one: 10% DMSO > > 90% corn oil Solubility: ≥ 0.6 mg/mL (1.24 mM); Clear solution 2.Add each solvent one by one: 10% DMSO > > 40% PEG300 > > 5% Tween-80 > > 45% saline Solubility: ≥ 0.6 mg/mL (1.24 mM); Clear solution 3.Add each solvent one by one: 10% DMSO > > 90% (20% SBE-β-CD in saline) Solubility: ≥ 0.6 mg/mL (1.24 mM); Clear solution Appearance : White crystalline powder Application : Anti-HIV Agents Storage : Powder: -20°C: 3 years 4°C: 2 years In solvent: -80°C: 6 months -20°C: 1 month Synonyms : MK-0518; MK 0518; MK0518; Raltegravir
More details are to be found here
Description : Raltegravir is a potent, selective, and orally bioavailable inhibitor of HIV integrase (IC50 = 15 nM). It is metabolized primarily by uridine diphosphate glucuronosyltransferase 1A. Raltegravir has long-term efficacy and safety in managing HIV-1 infection in adults, children, and adolescents. - Molecular Weight :482.514
- Melting Point :155-157˚C (dec.)
- Purity :98%
Molecular Formula : C20H20FKN6O5 Canonical SMILES : CC1=NN=C(O1)C(=O)NC(C)(C)C2=NC(=C(C(=O)N2C)[O-])C(=O)NCC3=CC=C(C=C3)F.[K+] InChI : InChI=1S/C20H21FN6O5.K/c1-10-25-26-17(32-10)16(30)24-20(2,3)19-23-13(14(28)18(31)27(19)4)15(29)22-9-11-5-7-12(21)8-6-11;/h5-8,28H,9H2,1-4H3,(H,22,29)(H,24,30);/q;+1/p-1 InChIKey : IFUKBHBISRAZTF-UHFFFAOYSA-M Solubility : In Vitro: H2O: 25 mg/mL (51.81 mM; Need ultrasonic) DMSO : 6 mg/mL (12.43 mM; Need ultrasonic) In Vivo: 1.Add each solvent one by one: 10% DMSO > > 90% corn oil Solubility: ≥ 0.6 mg/mL (1.24 mM); Clear solution 2.Add each solvent one by one: 10% DMSO > > 40% PEG300 > > 5% Tween-80 > > 45% saline Solubility: ≥ 0.6 mg/mL (1.24 mM); Clear solution 3.Add each solvent one by one: 10% DMSO > > 90% (20% SBE-β-CD in saline) Solubility: ≥ 0.6 mg/mL (1.24 mM); Clear solution Appearance : White crystalline powder Application : Anti-HIV Agents Storage : Powder: -20°C: 3 years 4°C: 2 years In solvent: -80°C: 6 months -20°C: 1 month Synonyms : MK-0518; MK 0518; MK0518; Raltegravir
More details are to be found here
More details are to be found here
More details are to be found here
More details are to be found here
More details are to be found here
|
|
|
Privileged suppliers
Last update 2024-05-31
|